Faricimab Treat-and-Extend for Diabetic Macular Edema

• Published in: Ophthalmology (Rochester, Minn.) Vol. 131; no. 6; pp. 708 - 723
• Main Authors: Haskova, Zdenka, Baumal, Caroline R., Csaky, Karl G., Murata, Toshinori, Ruamviboonsuk, Paisan, Silverman, David, Sun, Xiaodong, Wells, John A., Yoon, Young Hee, Abdulaeva, Elmira, Abraham, Prema, Adams, Serrhel, Adrean, Sean, Aliseda, Daniel, Bandello, Francesco, Barraza, Karen, Bertolucci, George, Borcz, Emilia, Bratko, Galina, Brown, Jamin, Cabrera, Francisco, Cagini, Carlo, Chen, Shih-Jen, Connolly, Brian, Desco, Carmen, Eter, Nicole, Fernandez Vega, Alvaro, Framme, Carsten, Fraser-Bell, Samantha, Fukutomi, Akira, Gallego-Pinazo, Roberto, George, Sheen, Ghorayeb, Ghassan, Goldstein, Michaella, Gomes, Nuno, Gonzalez, Victor, Heier, Jeffrey, Honda, Shigeru, Hu, Allen, Hurcikova, Maria, Jacoby, Rachael, Javey, Golnaz, Javid, Cameron, Kampik, Daniel, Karabas, Levent, Kawasaki, Tsutomu, Kimura, Kazuhiro, Kuriyan, Ajay, Kwong, Henry, Lai, Timothy, Lai, Chi-Chun, Lavinsky, Daniel, Liu, Judy, Marcus, Dennis, Mastropasqua, Leonardo, Maturi, Raj, McCabe, Frank, Mitamura, Yoshinori, Montero, Javier, Morugova, Tatiana, Murakami, Tomoaki, Noda, Kousuke, Oh, Kean, Olivier, Sebastien, Pearlman, Joel, Perente, Irfan, Peto, Tunde, Pieramici, Dante, Pollreisz, Andreas, Rathod, Rajiv, Rosenblatt, Irit, Schadlu, Ramin, Seitz, Berthold, Shimouchi, Akito, Sikorski, Bartosz, Singerman, Lawrence, Steinle, Nathan, Sugimoto, Masahiko, Takagi, Hitoshi, Tan, Gavin, Tlucek, Paul, Vela, Jose Ignacio, Weger, Martin, Weishaar, Paul, Williams, Thomas Reginald, Wolfe, Jeremy, Wong, James, Wong, David, Wong, Robert, Wowra, Bogumil, Wylęgała, Edward, Yasukawa, Tsutomu, Yates, Paul, Yoreh, Barak, Yoshida, Shigeo, Yu, Seung Young, Zaczek Zakrzewska, Karolina, Zambrano, Alberto, Zatorska, Barbara
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 01.06.2024
• Subjects: Angiopoietin-2; Diabetic macular edema; Faricimab; Vascular endothelial growth factor A; Vascular stability; IOI; AE; CST; ETDRS; CI; VEGF; Diabetic macular edema; Angiopoietin-2; DRSS; COVID-19; SD; T&E; BCVA; Vascular endothelial growth factor A; Faricimab; IRF; Vascular stability; DME; MMRM
• ISSN: 0161-6420
• DOI: 10.1016/j.ophtha.2023.12.026

To evaluate the 2-year efficacy, durability, and safety of dual angiopoietin-2 and vascular endothelial growth factor (VEGF) A pathway inhibition with intravitreal faricimab according to a personalized treat-and-extend (T&E)-based regimen with up to every-16-week dosing in the YOSEMITE and RHINE (ClinicalTrials.gov identifiers, NCT03622580 and NCT03622593, respectively) phase 3 trials of diabetic macular edema (DME). Randomized, double-masked, noninferiority phase 3 trials. Adults with visual acuity loss (best-corrected visual acuity [BCVA] of 25–73 letters) due to center-involving DME. Patients were randomized 1:1:1 to faricimab 6.0 mg every 8 weeks, faricimab 6.0 mg T&E (previously referred to as personalized treatment interval), or aflibercept 2.0 mg every 8 weeks. The T&E up to every-16-week dosing regimen was based on central subfield thickness (CST) and BCVA change. Included changes from baseline in BCVA and CST, number of injections, durability, absence of fluid, and safety through week 100. In YOSEMITE and RHINE (n = 940 and 951, respectively), noninferior year 1 visual acuity gains were maintained through year 2; mean BCVA change from baseline at 2 years (weeks 92, 96, and 100 average) with faricimab every 8 weeks (YOSEMITE and RHINE, +10.7 letters and +10.9 letters, respectively) or T&E (+10.7 letters and +10.1 letters, respectively) were comparable with aflibercept every 8 weeks (+11.4 letters and +9.4 letters, respectively). The median number of study drug injections was lower with faricimab T&E (YOSEMITE and RHINE, 10 and 11 injections, respectively) versus faricimab every 8 weeks (15 injections) and aflibercept every 8 weeks (14 injections) across both trials during the entire study. In the faricimab T&E arms, durability was improved further during year 2, with > 60% of patients receiving every-16-week dosing and approximately 80% receiving every-12-week or longer dosing at week 96. Almost 80% of patients who achieved every-16-week dosing at week 52 maintained every-16-week dosing without an interval reduction through week 96. Mean CST reductions were greater (YOSEMITE/RHINE weeks 92/96/100 average: faricimab every 8 weeks –216.0/–202.6 µm, faricimab T&E –204.5/–197.1 µm, aflibercept every 8 weeks –196.3/–185.6 µm), and more patients achieved absence of DME (CST < 325 μm; YOSEMITE/RHINE weeks 92–100: faricimab every 8 weeks 87%–92%/88%–93%, faricimab T&E 78%–86%/85%–88%, aflibercept every 8 weeks 77%–81%/80%–84%) and absence of intraretinal fluid (YOSEMITE/RHINE weeks 92–100: faricimab every 8 weeks 59%–63%/56%–62%, faricimab T&E 43%–48%/45%–52%, aflibercept every 8 weeks 33%–38%/39%–45%) with faricimab every 8 weeks or T&E versus aflibercept every 8 weeks through year 2. Overall, faricimab was well tolerated, with a safety profile comparable with that of aflibercept. Clinically meaningful visual acuity gains from baseline, anatomic improvements, and extended durability with intravitreal faricimab up to every 16 weeks were maintained through year 2. Faricimab given as a personalized T&E-based dosing regimen supports the role of dual angiopoietin-2 and VEGF-A inhibition to promote vascular stability and to provide durable efficacy for patients with DME. Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.